Antibody Drug Conjugate Targeting Matriptase for Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack specificity and often result in significant systemic toxicity, as they do not effectively target cancer cells, leading to unwanted side effects.
Innovation Solution
Development of an antibody drug conjugate (ADC) that specifically targets activated matriptase on the surface of malignant cells, using monoclonal antibodies conjugated with cytotoxic agents like doxorubicin or neocarzinostatin, to deliver the drug payload directly to tumor sites, reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy is used to treat cancer, then cancer cell growth is inhibited, but systemic toxicity and unwanted side effects occur due to lack of specificity
Solution Approach 1:
The therapy is segmented into two functional components: a monoclonal antibody component that provides specific targeting to cancer cells through recognition of matriptase antigen, and a cytotoxic agent component that provides killing activity. This segmentation allows the specific and toxic functions to be separated and optimized independently, with the antibody directing the toxin specifically to cancer cells, thereby reducing systemic toxicity while maintaining cancer cell targeting specificity.
Solution Approach 2:
The monoclonal antibody serves as an intermediary carrier that delivers the cytotoxic agent from the bloodstream to the cancer cell. The antibody binds to matriptase on the cancer cell surface and facilitates uptake of the conjugated toxin into the cell. This intermediary mechanism enables specific delivery of the harmful cytotoxic agent only to cancer cells expressing matriptase, avoiding harm to normal cells while maintaining targeted effectiveness.
2Productivity
If cytotoxic agents are delivered non-specifically to cancer cells, then cancer treatment is achieved, but normal cells are harmed causing unwanted side effects
Solution Approach 1:
The therapy imparts local quality by concentrating the cytotoxic effect specifically at cancer cells that express matriptase. The monoclonal antibody confers specificity through its unique binding affinity for matriptase, ensuring that the cytotoxic agent is delivered locally to the intended target. This local quality approach ensures high cancer cell killing efficiency while minimizing exposure of normal cells to the toxin, thereby reducing unwanted side effects.
3Reliability
If monoclonal antibodies are conjugated with cytotoxic agents to create ADCs, then specific delivery to tumor sites is achieved, but the complexity of the therapeutic preparation increases
Solution Approach 1:
The invention merges the monoclonal antibody and cytotoxic agent into a single conjugated entity (antibody-drug conjugate). This combining approach integrates the targeting function and killing function into one unified therapeutic molecule, simplifying the administration process to a single injection rather than separate therapies. While the conjugation process itself is complex, the merged product provides reliable specific delivery and eliminates the need for combination therapy protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADC effectively kills cancer cells by delivering cytotoxic agents specifically to tumor sites, minimizing harm to normal cells and reducing systemic toxicity, as demonstrated by its potency against various cancer cell lines while showing minimal effect on cells lacking matriptase expression.
Implementation Method 1
ADC's combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby delivering drug payload to the tumor sites by targeting an antigen e.g., matriptase, expressed on the surface of malignant cells
Data Source
AI summary
Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.